Warning: file_get_contents(http://api.eortc.be/biblio/Publications?$top=5&$orderby=Year+desc%2C+Id+desc&$expand=PublicationGroups&$filter=PublicationGroups%2Fany%28pg%3Apg%2FGroupId+eq+36%29+and+Status+eq+%27Published%27): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /app/odataframework/src/Emakina/ODataFramework/SimpleEndpoint.php on line 77

Pharmacology & Molecular Mechanisms


The Pharmacology and Molecular Mechanisms (PAMM) group aims to stimulate preclinical and clinical research in Europe in the fields of: pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenetics, pharmacogenomics, molecular mechanisms of anticancer drug effects and drug-related molecular pathology. Many publications in these fields come from collaborations with PAMM and other EORTC groups.

A PAMM sub-committee on Drug Discovery focuses on identifying, evaluating and developing new anticancer agents. To assess potential drugs, the group’s academic scientists have access to a large range of in vitro and in vivo systems, including orthotopic and genetically-modified mouse models.

Each year, the PAMM organises a winter meeting. This conference is a multidisciplinary event where scientists and physicians meet to share data and develop collaborations to improve drug development and translational research that travels “from the lab to the bed side”. There are oral presentations on the best papers submitted.

Main Achievements

The PAMM is an integral part of EORTC’s Translational Research Division, delivering information for projects with other disease-oriented groups, particularly in early-stage developments. These publications demonstrate the PAMM’s contribution to developing other anticancer treatments: ( link to the publication ) .

EORTC research in this field has led to the development and validation of temozolomide, one of the first anticancer agents that could cross the blood-brain barrier. Today, this drug combined with radiotherapy is the standard of care for Glioblastomas. (link to publication)

An EORTC study also demonstrated that the poor pharmacokinetic profile of E09 (eoquin, apaquizone) was an advantage in treating superficial bladder cancer. (link to publication)

Another clinical trial led to the European approval of trabectedin, a naturally-occurring molecule, to treat soft-tissue sarcomas and ovarian cancer.

Research Group

  • Chair

    Eric Raymond

    Hopital Beaujon AP-HP

    Clichy, France

  • Secretary

    Peters Godefridus

    Vrije Universiteit Medisch Centrum

    Amsterdam, Netherlands

  • Treasurer

    Annette Larsen

    Hôpital Saint Antoine (AP-HP)

    Paris, France

Scientific Committee

  • E. Chatelut - Toulouse, FR


    Institut Universitaire du Cancer Toulouse Oncopole

  • J. Ciccolini - Marseille, FR


    School of Pharmacy of Marseille

  • E. Giovannetti - Amsterdam, NL


    Vrije Universiteit University Medical Center

  • M. Hegi - Lausanne, CH


    Laboratory of Brain Tumor Biology and Genetics – CHUV

  • G. Hempel - Münster, DE


    Westfälische Wilhelms-Universität Münster

  • M. Joerger - St. Gallen, CH


    Kantonsspital St. Gallen

  • B. Leyland-Jones - Stanford , GB


    Stanford University School of Medicine

  • P. Perego - Milano, IT


    Istituto Nazionale dei Tumori di Milano

  • R. Phillips - Huddersfield , GB


    University of Huddersfield

  • C. Rolfo - Antwerp, BE


    University Hospital Antwerp

  • A. Skladanowski - Gdansk , PL


    Gdansk University of Technology

  • A. Westwell - Cardiff , GB


    Cardiff University

  • N. Zaffaroni - Milano, IT


    Istituto Nazionale dei Tumori di Milano